Excitingly, a combined approach using SMN-dependent ASO-inducing SMN2 exon inclusion and SMN-independent myostatin inhibition have shown a favorable result in an SMA animal model [120]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.